Journal of Surgical Oncology · 1992 · 10 citations · 11 references
MedicineOncologyPharmacologyCancer PharmacologyInflammationInnate ImmunityCytokines In Tumor ImmunityInflammatory SignalingLipid Emulsion TherapyLiposomal FormulationsLiposome-based DeliveryCationic LiposomesInflammatory Cytokine EffectsIntraperitoneal AdministrationLiposomes
Interleukin-2 was entrapped in liposomes (Lip-IL-2) and injected into rats. The intraperitoneal injection of Lip-IL-2 into rats bearing an ascites-forming rat hepatoma (AH-66) significantly increased the survival time when compared with rats administered free IL-2 or saline-containing liposomes. The number of peritoneal exudate cells (PEC) increased markedly after intraperitoneal injection of Lip-IL-2 and consisted mainly of macrophages. The level of tumor necrosis factor alpha (TNF-alpha) and the intensity of free radicals increased in the ascites at 48 hrs after Lip-IL-2 administration, whereas TNF-alpha was not detected and the intensity of free radicals did not increase after free IL-2 administration. Our findings suggested that entrapment of IL-2 into liposomes enhanced its potential for cancer therapy, presumably by activating macrophages to produce TNF-alpha and free radicals.
11
Oxygen-Dependent Microbial Killing by Phagocytes
Bernard Babior · New England Journal of Medicine · 1978 · 2.5K citations
S A Rosenberg, James J. Mulé, Paul J. Spiess et al. · The Journal of Experimental Medicine · 1985 · 741 citations · Full text
Medicine, Immunology, Oncology +13
Clinical effects and toxicity of interleukin-2 in patients with cancer
Michael T. Lotze, Yvedt L. Matory, Anthony A. Rayner et al. · Cancer · 1986 · 358 citations · Full text
Life Sciences, Immunology, Oncology +13
Isaiah J. Fidler, S Sone, William E. Fogler et al. · Proceedings of the National Academy of Sciences · 1981 · 323 citations · Full text
Medicine, Oncology, Pharmacology +17